Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
Adjuvant chemotherapy
Breast cancer
Guideline adherence
Guideline violation
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
31
05
2021
accepted:
01
12
2021
pubmed:
19
2
2022
medline:
23
4
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
This study examined 5-year overall, recurrence and distant metastasis-free survival (OS, RFS, MFS) of high- and intermediate-risk breast cancer (BC) patients who declined guideline-recommended adjuvant chemotherapy (CHT). In the prospective multicenter cohort study BRENDA II, patients with primary BC were sampled over a period of four years (2009-2012). A multi-professional team (tumorboard) discussed recommendation for adjuvant CHT according to the German guideline. Potential differences in 5 year survival were analyzed using Kaplan-Meier curves and Cox regression. The hazard ratios (HR) were adjusted for age, Charlson Comorbidity Score, American Society of Anesthesiologist (ASA) physical status classification, and endocrine therapy. A total of 759 patients were enrolled of which 688 could receive CHT according to the guidelines (n = 219 had a clear indication, in n = 304 it was possible). For 360 patients, the tumorboard advised to perform CHT, for 304 it advised against and in 24 cases, no decision was documented. Of those with a positive suggestion, 83% received CHT. Until 5 years after diagnosis, 57 patients were deceased, 41 had at least one distant metastasis and 29 a recurrence. There was no evidence for differences in OS and MFS in patients who declined CHT despite tumorboard recommendation (HR 3.5, 95% CI 0.8-15.1 for OS, HR 1.9, 95% 0.6-6.6 for MFS). Patients who received CHT had significantly better 5-year RFS compared to those who declined (HR 0.3, 95% CI 0.1-0.9, p = 0.03). There was no evidence for different survival in those who had no CHT because of comorbidity and those who declined actively, neither for OS, MFS nor RFS. The prospective BRENDA II study demonstrates benefit in RFS by guideline adherence in adjuvant breast cancer treatment, indicating prospectively the value of internationally validated guidelines in breast cancer care.
Sections du résumé
BACKGROUND
BACKGROUND
This study examined 5-year overall, recurrence and distant metastasis-free survival (OS, RFS, MFS) of high- and intermediate-risk breast cancer (BC) patients who declined guideline-recommended adjuvant chemotherapy (CHT).
METHODS
METHODS
In the prospective multicenter cohort study BRENDA II, patients with primary BC were sampled over a period of four years (2009-2012). A multi-professional team (tumorboard) discussed recommendation for adjuvant CHT according to the German guideline. Potential differences in 5 year survival were analyzed using Kaplan-Meier curves and Cox regression. The hazard ratios (HR) were adjusted for age, Charlson Comorbidity Score, American Society of Anesthesiologist (ASA) physical status classification, and endocrine therapy.
RESULTS
RESULTS
A total of 759 patients were enrolled of which 688 could receive CHT according to the guidelines (n = 219 had a clear indication, in n = 304 it was possible). For 360 patients, the tumorboard advised to perform CHT, for 304 it advised against and in 24 cases, no decision was documented. Of those with a positive suggestion, 83% received CHT. Until 5 years after diagnosis, 57 patients were deceased, 41 had at least one distant metastasis and 29 a recurrence. There was no evidence for differences in OS and MFS in patients who declined CHT despite tumorboard recommendation (HR 3.5, 95% CI 0.8-15.1 for OS, HR 1.9, 95% 0.6-6.6 for MFS). Patients who received CHT had significantly better 5-year RFS compared to those who declined (HR 0.3, 95% CI 0.1-0.9, p = 0.03). There was no evidence for different survival in those who had no CHT because of comorbidity and those who declined actively, neither for OS, MFS nor RFS.
CONCLUSION
CONCLUSIONS
The prospective BRENDA II study demonstrates benefit in RFS by guideline adherence in adjuvant breast cancer treatment, indicating prospectively the value of internationally validated guidelines in breast cancer care.
Identifiants
pubmed: 35178667
doi: 10.1007/s12282-021-01321-1
pii: 10.1007/s12282-021-01321-1
pmc: PMC9021155
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-436Informations de copyright
© 2022. The Author(s).
Références
Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2003;8(6):541–52. https://doi.org/10.1634/theoncologist.8-6-541 .
doi: 10.1634/theoncologist.8-6-541
pubmed: 14657533
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2007;18(7):1133–44. https://doi.org/10.1093/annonc/mdm271 .
doi: 10.1093/annonc/mdm271
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1,2018 AWMF Registernummer: 032-045OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
Schwentner L, Van Ewijk R, Kurzeder C, Hoffmann I, König J, Kreienberg R, et al. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer. 2013;49(3):553–63. https://doi.org/10.1016/j.ejca.2012.08.011 .
doi: 10.1016/j.ejca.2012.08.011
pubmed: 22959469
Wollschlager D, Meng X, Wockel A, Janni W, Kreienberg R, Blettner M, et al. Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. Breast J. 2018;24(2):120–7.
doi: 10.1111/tbj.12855
pubmed: 28685896
Ebner F, van Ewijk R, Wockel A, Hancke K, Schwentner L, Fink V, et al. Tumor biology in older breast cancer patients–what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients. Breast (Edinburgh, Scotland). 2015;24(3):256–62.
doi: 10.1016/j.breast.2015.02.029
Witherby SM, Muss HB. Special issues related to breast cancer adjuvant therapy in older women. Breast. 2005;14(6):600–11. https://doi.org/10.1016/j.breast.2005.08.015 (Epub 2005 Sep 29 PMID: 16198568).
doi: 10.1016/j.breast.2005.08.015
pubmed: 16198568
Takasugi M, Iwamoto E, Akashi-Tanaka S, Kinoshita T, Fukutomi T, Kubouchi K. General aspects and specific issues of informed consent on breast cancer treatments. Breast Cancer. 2005;12(1):39–44. https://doi.org/10.2325/jbcs.12.39 (PMID: 15657522).
doi: 10.2325/jbcs.12.39
pubmed: 15657522
Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O’Neil J, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997;277(18):1485–92 (PMID: 9145723).
doi: 10.1001/jama.1997.03540420081039
pubmed: 9145723
D’ Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson Comorbidity Index. Methods Inf Med. 1993;32:382–7.
doi: 10.1055/s-0038-1634956
Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, et al. A comparison of international breast cancer guidelines-do the national guidelines differ in treatment recommendations? Eur J Cancer. 2012;48(1):1–11.
doi: 10.1016/j.ejca.2011.06.020
pubmed: 21741830
Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21:3580–7.
doi: 10.1200/JCO.2003.02.046
pubmed: 12913099
Schwentner L, Van Ewijk R, Kühn T, Flock F, Felberbaum R, Blettner M, et al. Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II. Support Care Cancer. 2016;24(6):2759–66.
doi: 10.1007/s00520-016-3088-3
pubmed: 26816089
Leinert E, Singer S, Janni W, Harbeck N, Weissenbacher T, Rack B, et al. The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy: a comparative analysis from the prospective multicenter randomized ADEBAR trial. Clin Breast Cancer. 2017;17(2):100–6. https://doi.org/10.1016/j.clbc.2016.10.008 .
doi: 10.1016/j.clbc.2016.10.008
pubmed: 27884722
Leinert E, Schwentner L, Blettner M, Wöckel A, Felberbaum R, Flock F, et al. Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: results from the prospective multicenter BRENDA II study. Breast J. 2019;25(3):386–92. https://doi.org/10.1111/tbj.13231 .
doi: 10.1111/tbj.13231
pubmed: 30945393
Ho PJ, Ow SGW, Sim Y, et al. Impact of deviation from guideline recommended treatment on breast cancer survival in Asia. Sci Rep. 2020;10:1330. https://doi.org/10.1038/s41598-020-58007-5 .
doi: 10.1038/s41598-020-58007-5
pubmed: 31992769
pmcid: 6987174
Orucevic A, Heidel RE, Bell JL (2018) Outcomes of patients with invasive breast cancer (IBC) refusing standard cancer treatments: 10-year analysis of the National cancer data base (NCDB) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 78(4 Suppl):Abstract nr P6-08-19
Singer S, Blettner M, Kreienberg R, Janni W, Wöckel A, Kühn T, et al. Breast cancer patients’ fear of treatment: results from the multicenter longitudinal study BRENDA II. Breast Care (Basel). 2015;10(2):95–100. https://doi.org/10.1159/000381933 .
doi: 10.1159/000381933
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44. https://doi.org/10.1016/S0140-6736(11)61625-5 (Epub 2011 Dec 5).
doi: 10.1016/S0140-6736(11)61625-5
van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019;144(2):263–72. https://doi.org/10.1002/ijc.31914 .
doi: 10.1002/ijc.31914
pubmed: 30368776
Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and treatment of chemotherapy-induced cardiotoxicity. Methodist Debakey Cardiovasc J. 2019;15(4):267–73. https://doi.org/10.14797/mdcj-15-4-267 .
doi: 10.14797/mdcj-15-4-267
pubmed: 31988687
pmcid: 6977564
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26-35. https://doi.org/10.1016/j.breast.2015.07.008 (Epub 2015 Aug 5).
doi: 10.1016/j.breast.2015.07.008
pubmed: 26253814
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of humanbreast tumours. Nature. 2000;406(6797):747–52. https://doi.org/10.1038/35021093 (Epub 2000/08/30).
doi: 10.1038/35021093
pubmed: 10963602
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239–46. https://doi.org/10.1200/JCO.2006.07.1522.Erratum.In:JClinOncol.2007Aug20;25(24):3790 .
doi: 10.1200/JCO.2006.07.1522.Erratum.In:JClinOncol.2007Aug20;25(24):3790
pubmed: 17401012
Herr D, Wischnewsky M, Joukhadar R, Chow O, Janni W, Leinert E, et al. Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study. PLoS One. 2019;14(7): e0218434. https://doi.org/10.1371/journal.pone.0218434 .
doi: 10.1371/journal.pone.0218434
pubmed: 31283775
pmcid: 6613686
Matikas A, Foukakis T, Swain S, Bergh J. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? Ann Oncol. 2019;30(7):1044–50. https://doi.org/10.1093/annonc/mdz126 .
doi: 10.1093/annonc/mdz126
pubmed: 31131397
pmcid: 6695578
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. https://doi.org/10.1056/NEJMoa1804710 (Epub 2018 Jun 3).
doi: 10.1056/NEJMoa1804710
pubmed: 29860917
pmcid: 6172658
Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–29. https://doi.org/10.1056/NEJMoa1602253 .
doi: 10.1056/NEJMoa1602253
pubmed: 27557300
Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2—breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res. 2014;16(2):R38. https://doi.org/10.1186/bcr3642 .
doi: 10.1186/bcr3642
pubmed: 24725534
pmcid: 4076639
Kalinsky K, Barlow WE, Meric-Bernstam F, et al. (2020) First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/– chemotherapy (CT) in patients (pts) with 1–3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2–) breast cancer (BC) with recurrence score (RS) ≤ 25: SWOG S1007 (RxPonder). Presented at: 2020 San Antonio Breast Cancer Symposium; December 8–11; virtual. Abstract GS3-00. https://www.abstractsonline.com/pp8/#!/9223/presentations/rxponder/1